Health Care [ 3/12 ] | Health Care Equipment & Supplies [ 22/74 ]
NYSE | Common Stock
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally.
It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve.
In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure.
The company distributes its products through a direct sales force and independent distributors.
Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Oct 24, 24 | 0.67 Increased by +13.56% | 0.64 Increased by +4.69% |
| Jul 24, 24 | 0.70 Increased by +6.06% | 0.69 Increased by +1.45% |
| Apr 25, 24 | 0.66 Increased by +6.45% | 0.64 Increased by +3.13% |
| Feb 6, 24 | 0.64 Increased by 0.00% | 0.64 |
| Oct 25, 23 | 0.59 Decreased by -3.28% | 0.59 |
| Jul 26, 23 | 0.66 Increased by +4.76% | 0.65 Increased by +1.54% |
| Apr 26, 23 | 0.62 Increased by +3.33% | 0.61 Increased by +1.64% |
| Jan 31, 23 | 0.64 Increased by +25.49% | 0.61 Increased by +4.92% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 1.35 B Decreased by -8.54% | 3.07 B Increased by +697.82% | Increased by +226.73% Increased by +772.33% |
| Jun 30, 24 | 1.39 B Decreased by -9.43% | 366.30 M Increased by +19.28% | Increased by +26.43% Increased by +31.70% |
| Mar 31, 24 | 1.60 B Increased by +9.50% | 351.90 M Increased by +3.35% | Increased by +22.02% Decreased by -5.61% |
| Dec 31, 23 | 1.53 B Increased by +13.78% | 369.90 M Decreased by -7.15% | Increased by +24.11% Decreased by -18.40% |
| Sep 30, 23 | 1.48 B Increased by +12.27% | 384.90 M Increased by +12.05% | Increased by +25.99% Decreased by -0.20% |
| Jun 30, 23 | 1.53 B Increased by +11.38% | 307.10 M Decreased by -24.43% | Increased by +20.07% Decreased by -32.15% |
| Mar 31, 23 | 1.46 B Increased by +8.83% | 340.50 M Decreased by -8.86% | Increased by +23.33% Decreased by -16.25% |
| Dec 31, 22 | 1.35 B Increased by +1.40% | 398.40 M Increased by +18.82% | Increased by +29.55% Increased by +17.18% |